Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shionogi & Co Ltd (JP:4507)
:4507
Holding JP:4507?
Track your performance easily
Earnings Data
Report Date
Jan 31, 2025TBA Not Confirmed
Period Ending
2024 (Q3)Consensus EPS Forecast
47.07Last Year’s EPS
42.41Same Quarter Last Year
Moderate Sell
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2018
|% Change Since: 10.75%
|Next Earnings Date:Jul 30, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong performance in the HIV franchise and overseas growth, but offset by declines in overall revenue and profit, and challenges with COVID-19 product sales and regulatory approvals.Company Guidance
During the call, Shionogi & Co., Ltd. provided guidance on their financial and operational performance for the second quarter of fiscal year 2024, highlighting several key metrics. They reported a 7.2% year-on-year reduction in revenue and a 22.2% decline in operating profit. Despite these decreases, they maintained a positive outlook, projecting full-year growth with a revenue target of 4,600 billion yen and an operating profit of 1,650 billion yen. The company emphasized the strong performance of their HIV franchise, which saw a 26.6% increase in royalty income, contributing 120 billion yen in the first half of the year. Shionogi also reported an impressive market share for their COVID-19 treatment, Xocova, capturing 70% of the market. They discussed ongoing challenges and strategies, including efforts to increase the treatment rate from 13.4% to 15-17% and expanding their market share to 75-80%. For the second half, they anticipate achieving their revised upwards forecasts, with a focus on sustaining growth in both domestic and overseas markets.Strong Growth in HIV Franchise
The HIV royalty income increased by 26.6%, achieving 120 billion yen in the first half. ViiV's projections show a top line around 7 billion pounds by 2026, with more than one-third coming from long-acting treatments.
Overseas Revenue Growth
Revenue growth exceeded 30% in both the US and Europe, demonstrating strong international performance.
OTC Segment Expansion
The OTC segment achieved a 15% growth over the last year, continuing to record maximum revenue and profit.
Successful Phase 3 Trial for Xocova
The SCORPIO-PEP trial showed positive results in preventing infection among close contacts of COVID-19 patients, paving the way for regulatory discussions.
---
JP:4507 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JP:4507 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 28, 2024 | ¥2080.00 | ¥2114.00 | +1.63% |
| Jul 29, 2024 | ¥2219.47 | ¥2238.88 | +0.87% |
| May 13, 2024 | ¥2463.56 | ¥2509.61 | +1.87% |
| Jan 31, 2024 | ¥2298.25 | ¥2313.54 | +0.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Shionogi & Co Ltd (JP:4507) report earnings?
Shionogi & Co Ltd (JP:4507) is schdueled to report earning on Jan 31, 2025, TBA Not Confirmed.
What is Shionogi & Co Ltd (JP:4507) earnings time?
Shionogi & Co Ltd (JP:4507) earnings time is at Jan 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Shionogi & Co Ltd stock?
The P/E ratio of Shionogi & Co is N/A.
What is JP:4507 EPS forecast?
JP:4507 EPS forecast for the fiscal quarter 2024 (Q3) is 47.07.
---